LMNGF News and Press, BioVaxys Technology From 04/25/22

BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction Canada NewsWire VANCOUVER, BC , April 25, 2022 /CNW/ -- BioVaxys Technology Corp. ( CSE: BIOV, FRA:5LB, OTCQB:BVAXF) ( "BioVaxys"...

BioVaxys Expands Cancer Vaccine Platform Canada NewsWire BVX-0922 to Target Colorectal Cancer Under Investigator-Sponsored IND VANCOUVER, BC , March 30, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ( "BioVaxys" ...

BioVaxys Announces Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program in Collaboration with The Ohio State University Canada NewsWire VANCOUVER, BC , March 17, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV ) ( FRA: 5LB ) ( OTCQB: BVAXF) ...

BioVaxys Closes Final Tranche of Non-brokered Private Placement Canada NewsWire VANCOUVER, BC , Feb. 28, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it...

BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein Canada NewsWire SUGGESTS superior cardiAC safety compared to mRNA AND ADENOVIRUS VECTOR vaccines VANCOUVER, BC , Feb. 16, 2022 /CNW/ -- BioVaxys Technol...

BIOVAXYS CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENT Canada NewsWire VANCOUVER, BC , Feb. 10, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ( "BioVaxys" or the "Company") is pleased to announce that it has closed...

BIOVAXYS ANNOUNCES NON-BROKERED PRIVATE PLACEMENT Canada NewsWire VANCOUVER, BC , Feb. 8, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ( "BioVaxys" or the "Company") is pleased to announce a non-brokered private placement (t...

Biovaxys Announces Major Research Collaboration With The Ohio State University To Develop Broadly Reactive Pan-Sarbecovirus Vaccine Canada NewsWire VANCOUVER, BC , Dec. 7, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (" ...

BioVaxys Chief Medical Officer David Berd, MD, Invited by Editorial Board of Therapeutic Advances in Vaccines and Immunotherapy to Submit a Review Article on Haptenized Protein Vaccine Platform Canada NewsWire VANCOUVER, BC , Nov. 18, 2021 /CNW/ -- BioVaxys Tec...

BioVaxys Co-Founder and Chief Medical Officer David Berd, MD, to Present at World Vaccine & Immunotherapy Congress West Coast 2021 BioVaxys Co-Founder and Chief Medical Officer David Berd, MD, to Present at World Vaccine & Immunotherapy Congress West Coast 2021 Canad...